Kerry Lynn Reynolds

List of Publications by Year
in descending order

109 papers	5,479 citations	172207 29 h-index	102304 66 g-index
110 all docs	110 docs citations	110 times ranked	5258 citing authors

#	Article	IF	Citations
1	Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. Journal of the American Academy of Dermatology, 2023, 88, 246-249.	0.6	2
2	Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. American Journal of Kidney Diseases, 2022, 79, 134-137.	2.1	20
3	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
4	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrology Dialysis Transplantation, 2022, 37, 507-514.	0.4	10
5	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 2022, 40, 12-23.	0.8	75
6	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Antiâ€“Programmed Cell Death 1 and Antiâ€“Programmed Cell Death Ligand 1 Therapy. JAMA Dermatology, 2022, 158, 189.	2.0	60
7	Reninâ€“angiotensinâ€“aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. European Journal of Cancer, 2022, 163, 108-118.	1.3	21
8	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. Journal of the American Academy of Dermatology, 2022, 87, 1147-1149.	0.6	4
9	Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. Journal of the National Cancer Institute, 2022, 114, 1200-1202.	3.0	9
10	Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy. British Journal of Dermatology, 2022, 187, 424-426.	1.4	1
11	Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. European Journal of Cancer, 2022, 166, 21-23.	1.3	0
12	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 871452.	2.2	8
13	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. Journal of Investigative Dermatology, 2022, 142, 2896-2908.e4.	0.3	9
14	Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Dermatology, 2022, 158, 933.	2.0	20
15	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
16	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. Journal of Clinical Oncology, 2022, 40, 2507-2507.	0.8	1
17	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist, 2021, 26, 49-55.	1.9	18
18	Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitorâ€“induced gastroenterocolitis. European Journal of Cancer, 2021, 142, 143-146.	1.3	6

#	Article	IF	Citations
19	Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathology, 2021, 34, 426-437.	2.9	48
20	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
21	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2021, 1, ltab014.	1.2	10
22	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. Journal of Vascular and Interventional Radiology, 2021, 32, 187-195.	0.2	17
23	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
24	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	1.9	18
25	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. JACC: CardioOncology, 2021, 3, 35-47.	1.7	80
26	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
27	Myocardial T1 and T2 Mapping by Magnetic Resonance in PatientsÂWithÂImmune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	1.2	97
28	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e898-e901.	1.9	12
29	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
30	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.. Journal of Clinical Oncology, 2021, 39, 2655-2655.	0.8	0
31	Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatology, 2021, 157, 577.	2.0	31
32	Impact of systemic corticosteroids for cutaneous immune-related adverse events on survival outcomes in patients with advanced cancer: A retrospective cohort study.. Journal of Clinical Oncology, 2021, 39, e14523-e14523.	0.8	0
33	Consensus disease definitions for the spectrum of neurologic immune related adverse events.. Journal of Clinical Oncology, 2021, 39, 2647-2647.	0.8	2
34	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist, 2021, 26, e1427-e1433.	1.9	11
35	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Current Treatment Options in Oncology, 2021, 22, 53.	1.3	2
36	Impact of cancer type on the incidence of cutaneous toxicities after immune checkpoint inhibitor therapy: A population-level analysis.. Journal of Clinical Oncology, 2021, 39, e14553-e14553.	0.8	0

#	Article	IF	Citations
37	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
38	Relationship between insurance status and diagnosis of cutaneous immune-related adverse events.. Journal of Clinical Oncology, 2021, 39, e18535-e18535.	0.8	0
39	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist, 2021, 26, 685-693.	1.9	3
40	Multi-detector computed tomography (MDCT)â€“based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European Radiology, 2021, 31, 8868-8878.	2.3	2
41	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
42	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
43	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports, 2021, 23, 98.	1.3	34
44	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
45	Response to: â€œImmune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactionsâ€. Journal of the American Academy of Dermatology, 2021, 85, e111-e112.	0.6	0
46	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
47	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 157, 50-58.	1.3	9
48	Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, 36, 2241-2247.	0.4	33
49	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
50	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
51	Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. European Journal of Cancer, 2021, 159, 34-37.	1.3	5
52	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances, 2021, 3, v108-v120.	0.4	6
53	Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 994-996.	0.6	16
54	Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist, 2020, 25, 6-14.	1.9	31

#	Article	IF	Citations
55	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 743-746.	0.6	9
56	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
57	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation, 2020, 142, 2299-2311.	1.6	282
58	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American Heart Association, 2020, 9, e018306.	1.6	38
59	The Art of Oncology: COVID-19 Era. Oncologist, 2020, 25, 997-1000.	1.9	6
60	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	5.1	74
61	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney International Reports, 2020, 5, 1700-1705.	0.4	47
62	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
63	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. JAMA Network Open, 2020, 3, e2016144.	2.8	24
64	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
65	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kidney Medicine, 2020, 2, 373-375.	1.0	5
66	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
67	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. Cancer, 2020, 126, 3569-3578.	2.0	6
68	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. New England Journal of Medicine, 2020, 382, 1150-1159.	13.9	7
69	Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. Journal of the American Academy of Dermatology, 2020, 83, 1475-1477.	0.6	16
70	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 2020, 22, 39.	1.8	199
71	Performance status and endâ€ofâ€life care among adults with nonâ€“small cell lung cancer receiving immune checkpoint inhibitors. Cancer, 2020, 126, 2288-2295.	2.0	49
72	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of Neurology, 2020, 87, 659-669.	2.8	137

#	Article	IF	Citations
73	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	1.0	212
74	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research, 2020, 26, 2838-2848.	3.2	403
75	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. American Journal of Kidney Diseases, 2020, 76, 63-71.	2.1	74
76	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	1.2	179
77	Clinical Features and Outcomes of Immune Checkpoint Inhibitorâ€“Associated AKI: A Multicenter Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 435-446.	3.0	247
78	Diagnostic evaluation of immune checkpoint inhibitor (CPI) colitis: The role of CT scan.. Journal of Clinical Oncology, 2020, 38, 821-821.	0.8	0
79	Atypical Stevens-Johnson syndrome-like reaction in the setting of immune checkpoint inhibition.. Journal of Clinical Oncology, 2020, 38, 102-102.	0.8	0
80	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Medicine, 2019, 8, 4986-4999.	1.3	27
81	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer in the United States. JAMA Network Open, 2019, 2, e1911952.	2.8	47
82	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology, 2019, 93, e1093-e1103.	1.5	107
83	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
84	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	2.0	51
85	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist, 2019, 24, 435-443.	1.9	80
86	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist, 2019, 24, 735-742.	1.9	43
87	Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Seminars in Arthritis and Rheumatism, 2019, 48, 1127-1132.	1.6	56
88	Costâ€effectiveness of immune checkpoint inhibitors for microsatellite instabilityâ€“high/mismatch repairâ€“deficient metastatic colorectal cancer. Cancer, 2019, 125, 278-289.	2.0	24
89	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Nonâ€“Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncology, 2019, 5, 358.	3.4	48
90	Performance status, survival, and end-of-life care in adults with non-small cell lung cancer (NSCLC) treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, 49-49.	0.8	1

#	Article	IF	Citations
91	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 81-81.	0.8	0
92	Flu vaccination rate of patients with severe immune-related adverse events.. Journal of Clinical Oncology, 2019, 37, e18234-e18234.	0.8	1
93	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. Journal of Clinical Oncology, 2019, 37, 6634-6634.	0.8	2
94	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	1.2	997
95	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018, 132, 1037-1037.	0.6	1
96	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. Journal of Clinical Oncology, 2018, 36, 3060-3060.	0.8	4
97	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3087-3087.	0.8	2
98	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. Journal of Clinical Oncology, 2018, 36, 3096-3096.	0.8	4
99	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. Journal of Clinical Oncology, 2018, 36, 56-56.	0.8	1
100	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. Journal of Clinical Oncology, 2018, 36, 127-127.	0.8	10
101	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.. Journal of Clinical Oncology, 2018, 36, 829-829.	0.8	0
102	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. Journal of Clinical Oncology, 2018, 36, e16089-e16089.	0.8	0
103	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, e15134-e15134.	0.8	0
104	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646.	1.1	24
105	Neoadjuvant Endocrine Therapy for Estrogen Receptorâ€“Positive Breast Cancer. JAMA Oncology, 2016, 2, 1477.	3.4	259
106	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 586-586.	0.8	0
107	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. Journal of Clinical Oncology, 2014, 32, 2517-2517.	0.8	10
108	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 647-647.	0.8	0

#	Article	IF	Citations
109	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. Journal of Clinical Oncology, 2013, 31, 147-147.	0.8	1